Jennifer Robblee

Dr. Jennifer Robblee, a headache neurologist at the Barrow Neurological Institute, discusses groundbreaking migraine treatments: gepants and ditans. These new medications are reshaping acute migraine management, with fewer side effects compared to traditional triptans. The conversation highlights their effectiveness, including specific examples like ubrojapant and lasmititan. Dr. Robblee emphasizes the importance of personalized treatment plans to ensure the right therapies for individual patients, paving the way for a more innovative approach to migraine relief.

Jennifer Robblee, a physician specializing in refractory migraine research and guideline development, discusses why a standardized international definition for refractory migraine was needed. She walks through the consensus structure and key criteria. She also previews updated guidance for acute migraine treatment in the emergency department.

Jennifer Robblee, a board-certified neurologist and headache specialist, joins forces with Serena Orr, a pediatric neurologist, to discuss the latest 2025 guidelines on migraine treatments in emergency settings. They dive into the necessity for updates due to new evidence and ongoing practice variations. The duo emphasizes effective treatments like prochlorperazine and greater occipital nerve blocks, while warning against the use of hydromorphone. They also tackle practical implementation challenges and the need for more patient-centered research in headache management.